Clinical Trial Update: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of TGR-1202 and ruxolitinib in patients with myelofibrosis and polycythemia vera who are resistant to hydroxyurea; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• TGR-1202 (umbralisib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Myelofibrosis, Polycythemia Vera | Phase 1 | Status: COMPLETED